NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Medical Instruments & Supplies · USD

Repligen Corporation (RGEN) Stock Analysis

Repligen Corporation (RGEN) is a Medical Instruments & Supplies stock listed on NASDAQ and quoted in US Dollar.

RGEN

$167.60

−$2.01 (−1.19%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare RGEN with… →

RGEN Key Statistics

As of Sep 4, 2026
Trading
Open
$167.26
Previous Close
$169.61
Day's Range
165.00–169.51
52-Week Range
100.99–188.73
Volume
806.10K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.05
Valuation
Market Cap
$9.46B
P/E Ratio
226.49
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
63.54
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.69
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
12.05
EPS (ttm)Profit attributable to each share over the last twelve months.
0.74
Financials (FY)
Revenue (FY)
$738.26M+16.36%
Net Income (FY)
$48.89M
Profit marginThe share of revenue left as profit after all costs and taxes.
5.29%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
56.44M
1-Year Return
+38.99%
Dividend and dates
Earnings Date
November 3, 2026
Avg Volume
1.13M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

RGEN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+2.28%
2025+13.84%
2024−19.94%
2023+6.20%
2022−36.07%
2021+38.20%
2020+107.17%
2019+75.39%
2018+45.37%
2017+17.72%
2016 (partial year)+2.73%

As of September 4, 2026.

RGEN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$738.26M$48.89M6.6%
2024$634.44M−$25.51M−4.0%
2023$632.36M$35.60M5.6%
2022$801.54M$185.96M23.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$738.26M$386.25M$41.56M$48.89M6.6%
2024$634.44M$274.65M−$31.92M−$25.51M−4.0%
2023$632.36M$278.44M$17.13M$35.60M5.6%
2022$801.54M$455.71M$195.94M$185.96M23.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

RGEN Valuation vs Medical Instruments & Supplies Median

Median of 55 stocks
MetricRGENMedical Instruments & Supplies medianvs median
P/E226.4935.616.4x the median
P/S ratio12.053.173.8x the median
Profit margin5.29%0.85%4.4 pts above

Medians across 55 Medical Instruments & Supplies stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Repligen Corporation (RGEN) carries a market capitalisation of $9.46B. The company sits in the Healthcare sector, in the Medical Instruments & Supplies industry. The company reports 2,000 employees.

The 52-week range on file runs from $100.99 to $188.73. The most recent close on file for RGEN is $167.60, dated September 4, 2026. That is −$2.01 (−1.19%) against the previous close. The latest close sits 65.96% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $738.26M. Against the prior fiscal year total of $634.44M, that is a change of +16.36%. The same year closed with net income of $48.89M. The reported profit margin is 5.29%. That is 4.4 percentage points above the Medical Instruments & Supplies median of 0.85%. Earnings per share on a trailing basis come to 0.74.

Across the 4 fiscal years on file, revenue moves from $801.54M in 2022 to $738.26M in 2025. Of those 4 years, 3 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 226.49. That is 6.4 times the Medical Instruments & Supplies median of 35.61. On forward earnings the ratio is 63.54. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.69. Measured against sales, the shares trade at 12.05 times revenue. On price-to-sales that is 3.8 times the Medical Instruments & Supplies median of 3.17. 55 Medical Instruments & Supplies companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned +38.99%. Measured over 10 years, that is +18.23% a year compounded. Beta against the wider market is reported at 1.05. Daily returns over the trailing 10 years annualize to a volatility of 46.11%.

Growth & Income

The record shows no dividend for RGEN.

Across the complete calendar years on file, 2020 returned +107.17% and 2022 returned −36.07%. Of the 9 complete calendar years on file, 7 finished higher. 2026 is still running; the price is +2.28% year to date.

Peer Comparison

Repligen Corporation (RGEN) operates in the Medical Instruments & Supplies industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Repligen Corporation RGEN $9.46B 226.5
Intuitive Surgical, Inc. ISRG $131.38B 42.4
Becton, Dickinson and Company BDX $50.32B 32.0
Medline Inc. MDLN $49.23B 45.7

The Medical Instruments & Supplies industry average P/E ratio is 35.6x. Repligen Corporation trades at a P/E of 226.5.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Instruments & Supplies Stocks

ISRG

Intuitive Surgical, Inc.

$131.38B

 BDX

Becton, Dickinson and Company

$50.32B

 MDLN

Medline Inc.

$49.23B

 ALC

Alcon Inc.

$34.08B

 RMD

ResMed Inc.

$32.94B

 WST

West Pharmaceutical Services, Inc.

$23.93B
View all Medical Instruments & Supplies stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Repligen Corporation

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Visit website →